AZA spiro alkane derivatives as inhibitors of metalloproteases

A method of treating a disease selected from osteoarthritis and rheumatoid arthritis in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the following formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• X is CH2NRb;
• Y is (CH2)j;
• V is piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, pyridin-1-yl or 3,6-dihydropyridin-1-yl each substituted with 0-5 Re;
• V′ is phenyl substituted with 0-5 Re;
• Rb is H, C(O)O(CRb′Rc′)r-T, or C(O)(CRb′Rc′)r-T;
• Rb′ and Rc′ are both H;
• Re is H, C1-6 alkyl, OH, Cl, F, Br, I, CN, NO2, methoxy, ethoxy, n-propoxy, isopropoxy, phenoxy, benzyloxy, amino, (C104 alkyl)amino, (C2-8)dialkylamino, C(O)O(C1-4 alkyl), CONH2, CONH(C1-4 alkyl), CON(C1-4 alkyl)2, C1-6haloalkyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, benzyl, or phenethyl;
• T is H, C1-10 alkyl substituted with 0 to 5 Rb′;
• C2-10 alkenyl substituted with 0 to 5 Rb′, C2-10 alkynyl substituted with 0 to 5 Rb′, C3-13 carbocyclyl substituted with 0-3 Rb′, or heterocyclyl substituted with 0-5 Rb′;
• j is 1 or 2;
• and
• r is 0, 1 or 2.